Penetration of moxifloxacin into rat mandibular bone and soft tissue.
OBJECTIVE
Based on its in vitro activity and spectrum of activity, the new 8-methoxyquinolone antibiotic moxifloxacin (MXF) seems suited for the antibiotic therapy of odontogenic infections. Penetration into the relevant tissue is another prerequisite for clinical efficacy. For this reason, the levels of MXF in plasma, soft tissue, and mandibular bone were determined in an animal model with Wistar rats.


METHODS
Samples of 49 rats were analyzed. Tissue samples were homogenized and proteins were precipitated. The pharmacokinetic evaluation was conducted based on non-compartmental analysis.


RESULTS
The concentration-time courses of tissues show a more plateau-shaped curve compared to plasma. Calculated AUC (area under the curve) ratios tissue:plasma were M. masseter:plasma = 2.64 and mandibles:plasma = 1.13.


CONCLUSIONS
Administration of antibiotics is considered an important part of therapy during and/or after surgical procedures in the maxillofacial area. Because of the good penetration into bone and muscle tissues demonstrated in Wistar rats, MXF might be an option for clinical application in this indication.
Cachovan
Georg
G
Center of Oral and Dental Medicine, Department of Restorative and Preventive Dentistry, University of Hamburg, Hamburg, Germany. cachovan@uke.uni-hamburg.de
Nergiz
Ibrahim
I
Thuss
Uwe
U
Siefert
Hans-Martin
HM
Sobottka
Ingo
I
Oral
Okhan
O
Platzer
Ursula
U
Dogan-Onur
Ozen
O
D000539:Alveolar Process / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D000890:Anti-Infective Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001372:Aza Compounds / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D024841:Fluoroquinolones; D007239:Infections / Q000188:drug therapy; D008297:Male; D008334:Mandible / Q000187:drug effects / Q000378:metabolism; D008406:Masseter Muscle / Q000187:drug effects / Q000378:metabolism*; D000077266:Moxifloxacin; D010510:Periodontal Diseases / Q000188:drug therapy*; D011804:Quinolines / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014076:Tooth Diseases / Q000188:drug therapy*
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin